Understanding the Covishield Controversy: Exploring the Risk of Blood Clots

1. INTODUCTION

AstraZeneca and Oxford University collaborated to create the Covishield vaccine, which has proven to be an essential weapon in the fight against the Covid-19 epidemic. But there have recently been questions raised about its safety, especially in light of the uncommon risk of blood clots among patients.

2. BASICS OF COVISHIELD YOU SHOULD KNOW

The way that the viral vector vaccine Covishield, also known as AZD1222, works is by inducing the body's immune system to generate antibodies against the coronavirus. It is a cornerstone of many national immunisation campaigns and has been approved for use in emergencies in a number of nations.

3. CONTROVERY STARTS:- COVISHIELD PROBLEMS

Reports that connected the Covishield vaccine to blood clot cases, especially in the cerebral venous sinuses, sparked a controversy regarding the vaccine. This led to an investigation into the possible hazards connected to the vaccine by regulatory bodies and health authorities.

4. UNDERSTANDING BLOOD CLOTS

Blood thickens and clumps together to produce blood clots, which resemble gel. Even though aberrant blood clotting is a natural reaction of the body to injury, it can result in major health issues including pulmonary embolism and stroke.

5. HOW DANGEROUS COVISHIELD IS ?

Research has demonstrated that the danger of blood clots related to Covishield vaccination is incredibly low, happening in a very small percentage of recipients. The complete benefit-risk profile of the vaccine has been ascertained by regulatory bodies after extensive risk assessments.

6. DOES COVISHILED CAUSES BLOODCLOTS DIRECTLY OR JUST A COINCINDECE?

Experts are still debating whether Covishield causes blood clots directly or if the events are just lucky coincidences. The answer is:- To learn more about the possible connection between the vaccine and uncommon clotting episodes, epidemiological research is being conducted.

7. SORTING OUT WHO MIGHT BE MORE AT RISK WITH COVISHIELD

An individual's chance of developing blood clots following immunisation may be influenced by variables like age, gender, and underlying medical conditions. By using risk stratification, medical professionals can better identify high-risk patients and adjust their immunisation plans accordingly.

8. PLANS TO LOWER THE CHANCE OF PROBLEMS WITH COVISHIELD

Regulatory agencies have put in place improved monitoring and surveillance mechanisms to find and look into adverse events that happen after vaccination in an effort to reduce the danger of blood clots. Healthcare professionals are also taught to identify and rapidly treat clotting problems.

9. RESPONSES FROM GLOBE AND LESSONS LEARNED

Different countries have responded to the CoviShield issue in different ways; some have been more cautious and have taken regulatory action. However they have managed it, this incident highlights how important it is to have robust processes in place to monitor vaccination safety. It also teaches us the importance of collaborating to solve new issues as they arise.

10. CONCLUSION

The Covishield debate serves as a reminder of the fluidity of vaccine safety surveillance and the value of stakeholder cooperation and open communication. Even though the Covid-19 outbreak is over, the lessons we learnt from it will still influence how we handle public health emergencies in the future. Through resolving issues, putting risk reduction plans into action, and cultivating public confidence, we can create a more robust and resilient global health system that can efficiently handle any obstacles that may occur in the future.

 
CALL TO ACTION:- 

 You can ask me your questions and opinions regarding this topic in comments.

Let's meet in another blog with  exciting trending topic.

Thanks for reading.

Images by Author:- ROHIT GOUR